Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02363868 · ClinicalTrials.gov registry record
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
A clinical trial of Chronic Myeloid Leukemia (CML), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 186
- Enrollment target
- 1
- Study location
NCT02363868: Completed study of Chronic Myeloid Leukemia (CML), sponsored by Bristol-Myers Squibb.
NCT02363868 is a study of Chronic Myeloid Leukemia (CML) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 186 participants, above the 45-participant average among 7 other Chronic Myeloid Leukemia (CML) trials with a reported enrollment target (313% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02363868, a study of Chronic Myeloid Leukemia (CML), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
Primary Outcome
Average (mean) costs for patients receiving dasatinib or nilotinib as first line therapy
Conditions Studied
Study Locations (1)
South Carolina
- Franklin Pharmaceutical Consulting, Llc - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-11 |
What the finished NCT02363868 record still lists
NCT02363868 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 45-participant average among 7 other Chronic Myeloid Leukemia (CML) trials with a reported enrollment target (313% higher).
The record links to 1 condition, with Chronic Myeloid Leukemia (CML) appearing as the primary indexed condition, and to 0 interventions.
NCT02363868 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT02363868 about?
NCT02363868 is a clinical study titled "Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population". The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
What is the current status of trial NCT02363868?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2014-02. Estimated completion is 2014-11.
What conditions does trial NCT02363868 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia (CML).
Who is sponsoring clinical trial NCT02363868?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02363868 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia (CML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
COMPLETED · Phase 2
-
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia